Piramal Imaging's diagnostic amyloid PET agent F-18 florbetaben, branded as Neuraceq, has been approved by the FDA. Neuraceq is indicated for PET imaging of the brain to estimate beta amyloid plaque density in patients with cognitive impairment who are being evaluated for possible Alzheimer's disease. Piramal Imaging has partnered with IBA Molecular for manufacturing and distribution of Neuraceq.

Full Story:

Related Summaries